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Abstract
Background
The burden of non-communicable disease (NCDs) has grown rapidly in low- and middle-
income countries (LMICs), where populations are ageing, with rising prevalence of multi-
morbidity (more than two co-existing chronic conditions) that will significantly increase pres-
sure on already stretched health systems. We assess the impact of NCDmultimorbidity on
healthcare utilisation and out-of-pocket expenditures in six middle-income countries: China,
Ghana, India, Mexico, Russia and South Africa.
Methods
Secondary analyses of cross-sectional data from adult participants (>18 years) in the WHO
Study on Global Ageing and Adult Health (SAGE) 2007–2010. We used multiple logistic
regression to determine socio-demographic correlates of multimorbidity. Association
between the number of NCDs and healthcare utilisation as well as out-of-pocket spending
was assessed using logistic, negative binominal and log-linear models.
Results
The prevalence of multimorbidity in the adult population varied from 39% in Ghana to
336% in Russia. Number of visits to doctors in primary and secondary care rose substan-
tially for persons with increasing numbers of co-existing NCDs. Multimorbidity was associ-
ated with more outpatient visits in China (coefficient for number of NCD = 056, 95% CI =
046, 066), a higher likelihood of being hospitalised in India (AOR = 159, 95% CI = 145,
175), higher out-of-pocket expenditures for outpatient visits in India and China, and higher
expenditures for hospital visits in Russia. Medicines constituted the largest proportion of
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Conclusion
Multimorbidity is associated with higher levels of healthcare utilisation and greater financial
burden for individuals in middle-income countries. Our study supports the WHO call for uni-
versal health insurance and health service coverage in LMICs, particularly for vulnerable
groups such as the elderly with multimorbidity.
Introduction
Non-communicable diseases (NCDs) are the leading cause of global disease burden[1, 2], with
80% of NCD mortality occurring in low- and middle-income countries (LMICs)[3, 4]. As the
populations in these countries age, the prevalence of multimorbidity, defined as persons with
two or more co-existing chronic conditions, will likely increase[5–8]. A recent study in Scot-
land found that while only 2% of the study population aged less than 25 years had multimor-
bidity, this percentage increased to nearly 65% for those aged 65 to 84 years[5]. Despite the
growing prevalence of NCD multimorbidity in LMICs[9], there is little attention given to the
impacts of multimorbidity on individuals and health systems as opposed to single chronic dis-
ease[10, 11].
The United Nations High-Level Meeting on NCDs in 2011 stressed the enormous challenge
posed by the growing burden of NCDs for health systems in LMICs. Most LMICs have rela-
tively low levels of public expenditure on health and incomplete health insurance and health
service coverage[12–15]. The shortfall in public expenditure on health care is typically made
up by out-of-pocket (OOP) and other private expenditures on health. According to WHO, pri-
vate expenditures constituted up to 70% of total health expenditures in India, and more than
40% in Russia and China[16]. The heavily dependence of out-of-pocket expenditure to fund
health systems in many LMICs is concerning, as growing evidence suggests user charges
adversely affect health, in particular for the elderly and those with chronic illness[17–19]. The
impoverishing effect of healthcare related OOP expenditures on individuals and households in
LMICs has been well documented[20, 21]. Less is known about the effect of NCD multimor-
bidity on healthcare utilisation and out-of-pocket expenditures[15, 22].
This study uses nationally representative data from six middle-income countries; China,
Ghana, India, Mexico, Russia, and South Africa. Progress toward universal health coverage in
these countries has been mixed (see Table A, Fig A in S1 File for country characteristics). For
instance, China and Mexico have introduced policies which have resulted in dramatic progress
in achieving universal health coverage. After the establishment of the New Cooperative Medi-
cal Scheme, the population coverage of health insurance has increased substantially in China,
particularly in rural areas. However, patients are still required to pay a large proportion of
health expenditures through out-of-pocket payments[23, 24]. At the beginning of the millen-
nium, Mexico had a fragmented health system with several health insurance schemes covering
formal workers, government employees and the private sector with a large proportion of the
population falling out of the health insurance coverage net[25, 26]. However, since 2003,
Mexico implemented a national health insurance scheme (Seguro Popular) which offers health
insurance coverage for those not working in formal sector and previously excluded from social
health insurance. This scheme has improved coverage of health insurance in the country
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dramatically. Public spending on health care remains low in India at about 1% of Gross
Domestic Product with a minority of the population covered by any form of social or voluntary
health insurance[27]. Major national and state level health insurance schemes for the poor,
such as Rashtriya Swasthya Bima Yojna (RSBY), do not appear to have addressed the major
burden of out of pocket expenditure faced by households in the country[28].
The aim of the study is to look at the socio-demographic correlates of NCDmultimorbidity.
Furthermore, we examined the impact of NCD multimorbidity on healthcare utilisation and
out-of-pocket expenditures. We hypothesise that persons with multimorbidity will have sub-
stantially greater need for health care, with higher healthcare utilisation and out-of-pocket
expenditures due to their more complex clinical and health needs, than individuals with single
NCD[8, 29]. We analyse the source of out-of-pocket expenditures (i.e. medication, healthcare
provider fees, medical test) in persons with multimorbidity[30, 31]. We believe this is the first
study reporting multimorbidity levels, its socio-economic and demographic correlates, as well
as its impact on healthcare utilisation and healthcare expenditures using nationally representa-
tive data in multiple middle-income countries.
Methods
Sample and data
We used cross-sectional data from the World Health Organization (WHO) Study on Global
Ageing and Adult Health (SAGE) collected via nationally representative population surveys in
six middle-income countries: China, Ghana, India, Mexico, Russia and South Africa. The sur-
vey includes nationally representative cohorts of persons aged 50+ years, with a smaller cohort
of persons aged 18 to 49 for comparison purposes[32]. In brief, the aim of the SAGE is to
understand self-reported health problems, disability, healthcare utilisation and subjective well-
being of adult populations to inform evidence based policy making.[32] The survey objectives
and methods are detailed elsewhere.[32]
The data were collected simultaneously in multiple countries during 2007–10, with the total
sample size in six countries of 44,464 persons (sample size in China: 14785, Ghana: 5573,
India: 12198, Mexico: 2734, Russia: 4947, South Africa: 4227), and allow cross-country com-
parison of key health indicators.[33, 34] In our analysis, we included respondents aged18
years, excluding those who had missing values on study variables (114% of the sample). As val-
ues for out-of-pocket expenditures were highly skewed, we removed observations with the
highest 05% of out-of-pocket expenditures to lessen the skewing effects and influence of outli-
ers on the analysis.
Variables
Our main variable of interest was whether respondents had more than one NCD. In the SAGE,
the list of NCDs asked about were: angina, arthritis, asthma, cataracts, diabetes, stroke, chronic
lung disease, hypertension and depression. We defined respondents as having an NCD if
they answered affirmatively the following two questions: “Have you ever been told by a health
professional that you have. . .? (for example, arthritis)”, or “Have you ever been diagnosed
with. . .?”. We counted the number of NCDs for each respondent, and defined those with mul-
timorbidity as the presence of two or more of the above listed conditions without a specific ref-
erence condition.
Respondents were asked about their utilisation of outpatient and inpatient services; whether
or not they had any outpatient visit, and number of outpatient visits in the past 12 months; or
any overnight hospital stay in the past three years, and number of overnight stays in hospital in
the past 12 months. SAGE also collected information on how much respondents paid out-of-
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pocket for their last outpatient or inpatient visit including the treatment was free of charge.
The out-of-pocket expenditures were further categorised by types of service and items, includ-
ing healthcare provider fees, medicines, medical tests, transport and others. We calculated the
proportion of out-of-pocket expenditures on each type of service.
We included the following covariates in the analyses: age (18–29, 30–39, 40–49, 50–59, 60–
69, 70+ years), gender, residence (rural, urban), geographical regions (country specific state/
region variables), education (no formal education, primary school completed, secondary school
and above), health insurance status (with/without insurance), and wealth quintiles.
Statistical analysis
We used multiple logistic regression analysis to determine socioeconomic and demographic
correlates of having any one and multiple NCDs. We calculated the pooled estimate using data
from all countries, but also ran separate analyses in each country and reported adjusted odds
ratios (AOR) and 95% confidence intervals (CI). We assessed the association between number
of NCDs and whether the respondent had any outpatient/inpatient visit (the binary outcome
variable) using a logistic regression model, and estimated the number of outpatient visits or
hospital stays using negative binomial models.
We summarized the proportion of respondents who reported that their last health care visit
was free / incurred no charge. To reduce skewness for data on out-of-pocket expenditures, we
used a log-linear model to assess associations between the number of NCDs and spending,
where a constant equals to one was added to the outcome variable prior to the log-transforma-
tion. We did not undertake a pooled analysis of out-of-pocket expenditure as the variable was
measured in each country’s own currency. To examine whether there was differential effect of
multimorbidity in different population groups, we conducted subgroup analyses stratified on
rural / urban residence and wealth quintile using the same regression model, with stratification
variable dropped.
We tested for multicollinearity for covariates adjusted for in our analysis. The multicolli-
nearity diagnostics (Variance Inflation Factor) were all less than five, indicating that the
assumption of reasonable independence among predictor variables was met[35]. We presented
AOR for results in logistic regression model, and regression coefficient for results in negative
binomial and log-linear models. All data analysis was weighted to account for the complex,
multi-stage design of the SAGE survey. We performed the statistical analyses using Stata 131
(StataCorp).
Results
We analysed data from 39,213 respondents from six countries (n = 13,191 in China; 4,873 in
Ghana; 11,043 in India; 2,595 in Mexico; 4,268 in Russia; and 3,243 in South Africa). We pres-
ent respondents’ socioeconomic and demographic characteristics in each country in Table B in
S1 File. Overall, in the sample with six countries combined (the pooled analysis), the median
age of the respondents was 446 years (IQR = 35–53), 51% were female, 75% were married, and
49% were residing in an urban area. The mean number of NCDs and proportion of persons
with multimorbidity was lowest in Ghana (mean 023, with 39% having multimorbidity) and
highest in Russia (mean number of NCDs = 122, with 336% had multimorbidity).
Multimorbidity levels
The prevalence of multimorbidity increased substantially with age in all countries (Table 1). In
the pooled countries analysis, prevalence increased from 1.4% in 18–29 year olds to 40.0% in
those aged 70+ years (AOR = 45.62, 95% CI = 27.39, 77.99). We observed the most dramatic
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rise in Russia where the prevalence of multimorbidity increased from 1.5% in 18–29 year olds
to 66.2% in year those aged 70+ years. The prevalence of multimorbidity in the 70+ age group
was 16.3% in Ghana, 29% in South Africa, 29.6% in Mexico, 30.4% in India, 38.0% in China
and 66.2% in Russia (Fig 1). Overall, for the age 50 and above group, 26.8 percent of the popu-
lation has multimorbidity.
Table 1. Socio-demographic correlates of multimorbidity in SAGE countries.
China Ghana India Mexico Russia South Africa Pooled
(n = 13,191) (n = 4,873) (n = 11,043) (n = 2,595) (n = 4,268) (n = 3,243) (n = 39,213)
Age 18–29 — — — — — — —
30–39 1.14 (0.14,
9.36)
— 4.06 (2.15,
7.65)
1.06 (0.25,
4.49)
4.93 (0.54,
45.01)
2.80 (0.18,
42.46)
2.14 (1.22,
3.78)
40–49 5.94 (1.06,
33.31)
1.43 (0.27,
7.52)
7.82 (4.24,
14.43)
5.46 (1.31,
22.71)
15.61 (2.43,
100.36)
35.41 (3.63,
345.81)
7.08 (4.20,
11.94)
50–59 11.09 (2.04,
60.28)
3.20 (0.67,
15.21)
16.07 (8.82,
29.27)
5.79 (1.32,
25.29)
38.83 (5.64,
267.60)
60.93 (7.75,
479.01)
14.22 (8.67,
23.33)
60–69 27.19 (4.79,
154.25)
6.65 (1.42,
31.10)
23.39 (13.05,
41.94)
17.28 (4.34,
68.81)
72.53 (10.15,
518.12)
103.76 (12.53,
859.71)
27.75 (16.71,
46.06)
70+ 41.50 (7.54,
228.36)
10.64 (2.31,
49.10)
39.29 (20.89,
73.89)
14.28 (3.48,
58.57)
153.34 (22.11,
1063.72)
112.75 (13.73,
925.87)
45.62 (27.39,
75.99)
Gender Male — — — — — — —
Female 1.18 (0.85,
1.63)
0.98 (0.60,
1.59)
1.20 (0.97,
1.47)
3.22 (1.89,
5.50)
1.31 (0.88,
1.96)
3.92 (2.37,
6.47)
1.39 (1.17,
1.64)
Location Rural — — — — — — —
Urban 2.24 (1.57,
3.21)
1.41 (0.86,
2.31)
1.05 (0.81,
1.36)
3.73 (1.79,
7.79)
1.60 (1.03,
2.48)
1.62 (0.92,
2.85)
1.55 (1.30,
1.85)
Marital
Status
Married — — — — — — —
Not Married 0.98 (0.72,
1.32)
1.64 (1.09,
2.48)
0.94 (0.74,
1.20)
1.09 (0.55,
2.16)
1.19 (0.83,
1.69)
0.76 (0.50,
1.16)
1.05 (0.89,
1.23)
Education No formal — — — — — — —
Primary
completed
0.58 (0.31,
1.09)
0.54 (0.20,
1.45)
1.44 (1.04,
2.00)
1.08 (0.44,
2.69)
1.51 (0.58,
3.91)
0.81 (0.37,
1.78)
0.94 (0.71,
1.26)
High school
above
0.54 (0.31,
0.93)
0.90 (0.51,
1.59)
1.16 (0.87,
1.55)
0.32 (0.13,
0.78)
1.38 (0.56,
3.37)
0.62 (0.27,
1.43)
0.86 (0.65,
1.14)
Wealth Q1 (the
lowest)
— — — — — — —
Q2 0.96 (0.64,
1.42)
1.74 (0.94,
3.26)
1.12 (0.73,
1.72)
0.36 (0.14,
0.94)
1.42 (0.79,
2.57)
0.78 (0.32,
1.87)
1.04 (0.82,
1.32)
Q3 0.84 (0.59,
1.19)
1.69 (1.06,
2.68)
1.28 (0.90,
1.80)
0.87 (0.31,
2.42)
1.51 (0.83,
2.72)
1.11 (0.40,
3.07)
1.20 (0.95,
1.52)
Q4 0.95 (0.58,
1.55)
5.31 (2.58,
10.93)
1.33 (0.93,
1.91)
0.61 (0.24,
1.56)
1.26 (0.63,
2.51)
1.07 (0.46,
2.52)
1.24 (0.95.
1.63)
Q5 (the
highest)
1.22 (0.70,
2.13)
4.80 (2.83,
8.13)
1.43 (0.99,
2.07)
0.98 (0.38,
2.51)
1.62 (0.95,
2.77)
1.33 (0.57,
3.09)
1.47 (1.15,
1.89)
Notes
1. Multimorbidity deﬁned as two or more chronic conditions in the same individual
2. Additional covariates included in the model in China: provinces; Ghana: ethnic groups (Akan, Ga-Adangbe, and others); India: states; South Africa:
provinces, ethnic groups (back, white, coloured, and others).
3. Country dummy variables were included in the model to adjust for heterogeneity among countries in the pooled analysis.
doi:10.1371/journal.pone.0127199.t001
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Socio-demographic correlates of multimorbidity
The prevalence of multimorbidity was higher in urban compared to rural areas (AOR = 1.55,
95% CI = 1.30, 1.85 in the pooled analysis). This association was observed in all countries
except India and Ghana. In three countries studied (India, Ghana and Russia), persons in the
highest wealth quintile were more likely to have multimorbidity, compared with the poorest
(AOR = 1.47, 95% CI = 1.15, 1.89 in pooled analysis).
Multimorbidity and healthcare utilisation
An increased number of NCDs was associated with a higher likelihood of having an outpatient
visit in the last year (Table 2, Fig 2). For example, in China, the percentage of respondents hav-
ing any outpatient visits in the past year increased from 46% for those without any NCDs to
63% for those with more than three NCDs (AOR = 1.50, 95% CI = 1.32,1.72). In South Africa,
the percentage of respondents having any outpatient visits increased from 26% for those with-
out any NCD to 81% for those with multimorbidity (AOR = 2.12, 95% CI = 1.59, 2.84). In the
pooled analysis, the percentage of respondents having an outpatient visit increased from 51%
for those without any NCD to 72% for those with multimorbidity (AOR = 1.51, 95% CI = 1.40,
1.64).
Number of NCDs was associated with increased number of outpatient visits in the last 12
months. For example, in India, the mean number of outpatient visits increased from 2.23 for
those without any NCD to 5.03 for those with multimorbidity (coefficient = 0.29, 95%
CI = 0.24, 0.34). In Mexico, the mean number of outpatient visits increased from 1.38 for those
without any NCD to 2.50 for those with multimorbidity (coefficient = 0.33, 95% CI = 0.08,
0.57). In the pooled analysis, the mean number of outpatient visits increased from 1.45 for
those without any NCD to 4.15 for those with multimorbidity (coefficient = 0.43, 95%
CI = 0.38, 0.47).
An increased number of NCDs was associated with a higher likelihood of having any hospi-
talisation over the last three years in all countries (Fig 3). For instance, in Russia, the propor-
tion having any hospital stay increased from 11% for those without any NCDs to 35% for those
with more than three NCDs (AOR = 1.53, 95% CI = 1.26, 1.85). In the pooled analysis, the pro-
portion of having any hospital stay increased from 9% for those without any NCDs to 28% for
those with NCDmultimorbidity (AOR = 1.63, 95% CI = 1.52, 1.75).
Fig 1. Prevalence of multimorbidity by age groups in SAGE countries.
doi:10.1371/journal.pone.0127199.g001
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An increased number of NCDs was associated with an increased number of hospitalisation
days in the last 12 months in all countries. For example, in Ghana, the mean number of hospi-
talisation days increased from 0.09 for those without any NCDs to 0.14 for those with multi-
morbidity (coefficient = 0.41, 95% CI = 0.13, 0.68). In the pooled analysis, the mean number of
hospitalisation days increased from 0.07 for those without any NCDs to 0.25 for those with
multimorbidity (coefficient = 0.49, 95% CI = 0.40, 0.57).
Multimorbidity and out-of-pocket expenditures
The percentage of doctor visits that were free of charge for outpatient and inpatient care are
presented in Fig 4A and 4B. Our results suggest less than 5% of respondents who reported that
Table 2. Association between number of NCDs and healthcare utilisation.
China Zero NCD One NCD Multi-Morbidity
Outpatient Any visit (%) 0.46 0.61 0.63
Number of visits (mean) 1.14 2.96 4.49
Inpatient Any hospitalisation 0.09 0.20 0.28
Hospitalisation days 0.07 0.17 0.23
Ghana Zero NCD One NCD Multi-Morbidity
Outpatient Any visit 0.52 0.65 0.81
Number of visits 1.28 2.27 3.78
Inpatient Any hospitalisation 0.11 0.17 0.14
Hospitalisation days 0.09 0.18 0.14
India Zero NCD One NCD Multi-Morbidity
Outpatient Any visit 0.71 0.84 0.86
Number of visits 2.23 3.22 5.03
Inpatient Any hospitalisation 0.09 0.15 0.25
Hospitalisation days 0.06 0.14 0.23
Mexico Zero NCD One NCD Multi-Morbidity
Outpatient Any visit 0.29 0.35 0.38
Number of visits 1.38 2.00 2.59
Inpatient Any hospitalisation 0.09 0.18 0.17
Hospitalisation days 0.01 0.06 0.20
Russia Zero NCD One NCD Multi-Morbidity
Outpatient Any visit 0.44 0.67 0.72
Number of visits 0.96 1.51 3.28
Inpatient Any hospitalisation 0.11 0.22 0.35
Hospitalisation days 0.08 0.17 0.31
South Africa Zero NCD One NCD Multi-Morbidity
Outpatient Any visit 0.26 0.50 0.81
Number of visits 0.72 2.63 5.74
Inpatient Any hospitalisation 0.06 0.09 0.21
Hospitalisation days 0.10 0.10 0.20
Pooled Zero NCD One NCD Multi-Morbidity
Outpatient Any visit 0.51 0.65 0.72
Number of visits 1.45 2.66 4.15
Inpatient Any hospitalisation 0.09 0.18 0.28
Hospitalisation days 0.07 0.15 0.25
doi:10.1371/journal.pone.0127199.t002
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their last health care visit was free in China and India. More than half of doctor visits for outpa-
tient services in Russia and South Africa were free of charge.
Out-of-pocket expenditures incurred in the last visit for outpatient and inpatient services
are presented in Table 3. There was a positive association between the number of NCDs and
outpatient OOP expenditure in China and India, but the reverse was observed when looking at
the inpatient visits in South Africa. In China, mean expenditure for outpatient services in the
last visit increased from 124.4 in respondents with no NCD to 179.2 Chinese yuan in respon-
dents with NCDmultimorbidity (coefficient = 0.21, 95% CI = 0.12, 0.31). In India, mean OOP
expenditure for outpatient service in the last visits increased from 262.2 in respondents with no
NCD to 431.0 Indian rupees in respondents with NCDmultimorbidity (coefficient = 0.25, 95%
CI = 0.18, 0.33). We did not find an increase in inpatient OOP expenditures during the last
visit with number of NCDs in any country, except Russia (coefficient = 0.76, 95% CI = 0.37,
1.15). Inpatient OOP expenditure was negatively associated with number of NCDs in South
Africa (coefficient = -0.43, 95% CI = -0.79, -0.07).
Fig 2. Association between number of NCDs and healthcare utilisation- any outpatient utilisation (Fig
2a); Association between number of NCDs and healthcare utilisation- number of outpatient visits (Fig
2b). Figures in the last column are coefficients and 95%CI for the variable “number of NCD” from regression
models adjusting for all covariates. Logistic model is used to estimate any visit for outpatient/inpatient service,
and negative binomial model is used for number of visit/ hospitalisation days outcome.
doi:10.1371/journal.pone.0127199.g002
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Our stratified analyses (Table C in S1 File) indicate that the association between multimor-
bidity and healthcare utilisation and OOP expenditure were broadly similar across population
in different wealth groups, and geographic locations (urban vs rural).
Source of out-of-pocket expenditures in outpatient and hospital settings
Patterns of out-of-pocket spending by type of service for persons with multimorbidity are pre-
sented in Fig 5 and Tables E and F within S1 File. For outpatient services, medicines constituted
the highest proportion of out-of-pocket expenditures for persons with multimorbidity in
China (83.5%) and India (61.0%). The proportion of out-of-pocket expenditure for healthcare
providers varied greatly between countries, ranging from 4.2% in Russia to 65.9% in South
Africa. Transport cost constituted a substantial proportion of spending in Ghana (38.5%),
South Africa (20.1%), and Mexico (18.8%). For inpatient services, medicines constituted the
highest proportion of out-of-pocket expenditures in China (60.6% of total out-of-pocket
expenditures) and India (49.2%). The proportion spent on inpatient healthcare provider fees
varied greatly in each country; from 73.2% in South Africa to 3.2% in Russia.
Fig 3. Association between number of NCDs and healthcare utilisation- any inpatient utilisation (Fig
3a); Association between number of NCDs and healthcare utilisation- number of inpatient visits (Fig
3b). Figures in the last column are coefficients and 95%CI for the variable “number of NCD” from regression
models adjusting for all covariates. Logistic model is used to estimate any visit for outpatient/inpatient service,
and negative binomial model is used for number of visit/ hospitalisation days outcome.
doi:10.1371/journal.pone.0127199.g003
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Discussion
Main findings
Using nationally representative data from the WHO SAGE, we believe this is the first study to
examine the prevalence of multimorbidity in six middle-income countries, its impact on
healthcare utilisation and out-of-pocket spending.[29, 36, 37] We found the prevalence of mul-
timorbidity in the adult population to vary markedly, from 3.9% in Ghana to 33.6% in Russia.
Consistent with earlier studies, we found that the prevalence of multimorbidity rises substan-
tially with increasing age, and is higher among persons living in urban areas.[5, 8, 38–40] We
identified a higher prevalence of multimorbidity among the most affluent groups, which con-
trasts with some earlier studies from LMICs.[5, 36] This could be due to self-reporting of NCD
status in our data, as respondents from higher socioeconomic background have better access to
health services resulting in better diagnoses of their NCDs[37].
Our results revealed that NCD multimorbidity is associated with greater healthcare utilisa-
tion and greater financial burden for citizens in the countries studied–burden mainly driven by
increased healthcare utilisation (for both primary and secondary care), and in some cases by
higher out-of-pocket expenditures per visit; findings consistent with earlier studies conducted
Fig 4. Proportion of respondents reporting that their last outpatient visit was free of charge (Fig 4a);
Proportion of respondents reporting that their last inpatient visit was free of charge (Fig 4b).Data
sourceWorld Health Organization (WHO) Study on Global Ageing and Adult Health (SAGE) survey, wave 1.
doi:10.1371/journal.pone.0127199.g004
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in high-income settings. For example, using a national representative sample in the United
States, Hwang et al.[31] found that mean out-of-pocket spending was nearly five times greater
in persons with more than three NCDs compared to those without any NCDs.
Consistent with earlier studies showing the impoverishing effect of purchasing medicines in
developing countries[41], our study found spending on medicines constituted a significant
proportion of total healthcare expenditures for those with multimorbidity. For example, in
China, it constituted 83.5% of outpatient service spending, and 60.6% of inpatient service
spending. Our data also shows that a sizeable proportion of out of pocket expenditures were
for transport costs, especially in Mexico, Russia, and South Africa.
While there was a high degree of consistency in our country level results, a number of
important variations are worth considering. For example, the prevalence of multimorbidity
was markedly higher in Russia than in other countries. This could be due to higher disease bur-
den, lower rates of undiagnosed conditions or measurement bias. We found the greater burden
of chronic conditions on out-of-pocket spending in countries such as China and India where
patients are required to pay a high level of patient cost sharing even for those have health insur-
ance. Whereas, in contrast to other countries, out-of-pocket spending did not increase with
more NCDs which reflects that primary care is provided free of charge in South Africa. It is
noteworthy that utilization of secondary care followed similar pattern with increasing NCDs as
that seen in other countries suggesting that removing financial barriers to accessing primary
care may not attenuate the greater risk of hospital admissions in persons with multimorbidity
[42].
Strength and limitations
Our findings are based on a large, nationally representative sample, which provides robust
cross-national level estimates of our key variables27,28, but several caveats merit discussion.
Table 3. Association between number of NCDs and out-of-pocket spending.
China (in yuan) Zero NCD One NCD Multimorbidity Regression Coefﬁcient
Outpatient 124.4 131.6 179.2 0.21 (0.12, 0.31)
Inpatient 4927.0 4160.9 3782.5 -0.08 (-0.28, 0.11)
Ghana (in cedi) Zero NCD One NCD Multimorbidity Regression Coefﬁcient
Outpatient 104915.4 102665.1 80534.5 0.33 (-0.98, 0.31)
Inpatient 606336.4 1023590.0 560583.2 0.09 (-0.76, 0.96)
India (in rupee) Zero NCD One NCD Multimorbidity Regression Coefﬁcient
Outpatient 262.2 340.2 431.0 0.25 (0.18, 0.33)
Inpatient 7653.4 6618.7 6942.1 0.09 (-0.09, 0.26)
Mexico (in peso) Zero NCD One NCD Multimorbidity Regression Coefﬁcient
Outpatient 208.1 183.8 468.8 0.43 (-0.03, 0.88)
Inpatient 3641.7 7346.6 2023.1 0.17 (-0.76, 1.10)
Russia (in ruble) Zero NCD One NCD Multimorbidity Regression Coefﬁcient
Outpatient 500.7 356.7 331.3 -0.02 (-0.25, 0.20)
Inpatient 1012.4 708.8 1558.3 0.76 (0.37, 1.15)
South Africa (in rand) Zero NCD One NCD Multimorbidity Regression Coefﬁcient
Outpatient 53.6 17.2 43.7 -0.24 (-0.46, -0.01)
Inpatient 770.4 5499.0 555.6 -0.43 (-0.79, -0.07)
Notes: Figures in the last column are regression coefﬁcients and 95% CI for the variable “number of NCD” from regression models adjusting for all
covariates. Log-linear models is used to estimate both outpatient and inpatient out-of-pocket spending outcomes.
doi:10.1371/journal.pone.0127199.t003
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First, the use of survey data and self-reported measures of NCDs are a potential source of bias,
including the potential for greater under-reporting of NCDs in persons from lower socioeco-
nomic backgrounds[37, 43, 44]. Although SAGE asks about nine common NCDs, the list is not
exhaustive and some common NCDs were not included[39]. Self-reporting of healthcare utili-
sation and out-of-pocket spending is prone to recall error especially in older populations.[45]
There were fewer respondents experienced any hospitalisation over the last year, we have small
sample size of less than a hundred observations in some countries when estimating the out-of-
pocket spending for their inpatient services. It is warranted for further studies to use adminis-
trative or survey dataset with a larger sample to investigate out-of-pocket expenditure made by
patients with multimorbidity. Second, SAGE data does not have information on non-medical
out-of-pocket expenditures, spending associated with home care and loss of employment
income which could be considerable for patients with multiple chronic illnesses.[29, 30]
Healthcare utilisation was not specific for NCDs, and may include patient’s visit for communi-
cable and other acute conditions, which may or may not relate to NCDs. Measures for
Fig 5. Percentage of out-of-pocket spending for each type of outpatient service in persons with
multimorbidity (Fig 5a); Percentage of out-of-pocket spending for each type of inpatient service in
persons with multimorbidity (Fig 5b). Estimates presented here are based on respondent’s healthcare visit
that was not free of charge.
doi:10.1371/journal.pone.0127199.g005
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utilisation and expenditure may also not reflect the actual financial burden associated with
NCDs, as patients with multiple NCDs may have forgone some treatments because of the
anticipated cost related to treatment.[46] Third, we assessed multimorbidity by counting the
number of NCDs without applying any weights to account for severity of conditions.[7]
Fourth, the cross-sectional study design limits causal interpretation of our findings. As all of
these countries have plans to widen health insurance coverage and reduce patient cost sharing,
further evidence is needed to assess the causal impact of these policies on healthcare utilisation,
medical adherence and patient’s health using longitudinal data.
Policy implications of findings
Our study provides further evidence for policies and targeted interventions to tackle the grow-
ing burden of NCDmultimorbidity. Despite the growing prevalence of multimorbidity, current
clinical practice frequently emphasise a single-disease specific approach. Our findings suggest
more focus should be placed on how best to treat multiple chronic conditions and multiple
risks associated with these with a patient-centred approach that fosters greater integration of
primary health care based services in health systems.[47] The National Institute for Health and
Care Excellence (NICE) in the UK is beginning to develop clinical guideline for multimorbid-
ity, and such efforts are warranted in LMICs where has different health systems with those in
high income countries[5, 48]. For example, many LMICs do not have a clear separation of the
primary and secondary care as that in the UK, and patients can see specialist without a referral
from their general practitioner (GP)[49, 50].
Stronger health systems underpinned by primary health care (PHC) are crucial to effectively
manage NCDs and risk factors for them, as PHC is often the first gateway to health services for
people with NCDs and plays a central co-ordinating role in the prevention, diagnosis and long-
term management of chronic diseases. Clinical guidelines for chronic care and integrated mod-
els of care for treating patients with multiple chronic diseases would help to achieve better
management of individuals with multimorbidity.[48, 51] Concerted efforts are also needed to
improve primary health care not only for treatment of chronic diseases but also to reduce pop-
ulation risk factors for NCDs through intersectoral health promotion and other primary and
secondary prevention.[47, 52]
Our results revealed a significant proportion of the sample populations in Mexico (12.6%),
Russia (19.4%) and South Africa (10.4%) aged 40–49 years also reported two or more NCDs;
this suggests that interventions for those with multimorbidity should not be restricted to older
age groups. As most of the NCDs are preventable, more evidence is needed to evaluate the
effectiveness and cost-effectiveness of health policies to reduce burden of NCDs such as inter-
ventions to improve diet and physical activity[53].
This study has shown greater financial burden for those with NCDmultimorbidity in
LMICs. Our results can be seen as elasticity of NCDs and healthcare utilization and out-of-
pocket spending, and these can be used to populate forecasting models to predict future burden
of the NCDs. The forecasting models can further assess the potential impact of preventive poli-
cies on NCDs and the economic consequences of these policies[54]. More investment for
health and financial innovations as well as affordable health technologies are needed to protect
those with chronic diseases[55, 56]. Universal health insurance should be at the centre of poli-
cies to promote fair financing and better access to health services across whole populations.
[57] Equitable access to effective and safe medicines remains a challenge in LMICs, and issues
such as the high cost of branded compared with generic medicines must be addressed to
expand access[58]. User fees have detrimental effect on adherence to medicine for patients
with chronic conditions, and that there is evidence to suggest that reducing medication co-
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payments does not lead to an increase in overall health expenditure by governments.[59–61]
Further research is required to better understand the additional demands of multimorbidity on
health systems and the cost-effectiveness of different strategies to reduce the burden of multi-
morbidity on individuals and health systems in LMICs.
Our findings supports the WHO call for universal health coverage in LMICs[62], in particu-
lar for vulnerable groups such as the elderly who are more likely to have multiple NCDs and
incur out-of-pocket expenditures and hence risk impoverishment. Our results have shown that
payment for medicines constitute a significant proportion of healthcare spending for those
with multimorbidity–with high levels of out-of-pocket expenditures that risk impoverishment.
Efforts are needed to lower patient cost sharing for essential and cost-effective treatments to
improve financial protection for patients with NCDs and multimorbidity. Decisive action is
critical for effective management of NCDs, multimorbidity and the risk factors that determine
them if WHO 25x25 targets are to be achieved, vulnerable groups protected from illness-
related impoverishment, and the promise of grand convergence in global health outcomes real-
ised.[63, 64]
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